Anti-CD19 CAR-T cell therapy with defined T-cell subsets for ibrutinib-refractory CLL – presentation at iwCLL 2017 – Lymphoma Hub
Lymphoma Hub |
Anti-CD19 CAR–T cell therapy with defined T-cell subsets for ibrutinib-refractory CLL – presentation at iwCLL 2017
Lymphoma Hub Maloney began by explaining that CAR–T cells produced from distinct T-cell subsets differ in potency. NSG mice bearing Raji tumors (0.5×106 tumor cell inoculation; day 0) were treated with human CAR–T cells manufactured from distinct T-cell subsets (on … |
